And as Mr. Trump moves to flesh out one of his more popular campaign promises, drugmakers may have reason to mobilize. During the presidential campaign, Mr. Trump embraced positions on this issue long held by Democrats — and long opposed by his party and the pharmaceutical industry. They are now worried about the proposals Mr. Trump may push to lower drug prices. But the lobbyists worry that Mr. Trump could easily veer off script, either on Twitter or in extemporaneous remarks in the coming weeks. “Nearly every major decision in this administration so far has favored the pharmaceutical industry,” said Ronny Gal, a securities analyst at Sanford C. Bernstein & Company.

Source: New York Times May 06, 2018 16:18 UTC